Drug intelligence / Profile preview

Immunsil

Development stage
Unknown
Lead developer
NutriMed Group
Modality
Small Molecules
Administration
Oral
01

Overview

Immunsil is an immunomodulatory dietary supplement developed by NutriMed Group, primarily marketed for strengthening the immune system and preventing respiratory infections. The formulation typically centers on high-purity beta-1,3/1,6-glucans derived from the cell walls of *Saccharomyces cerevisiae*. These polysaccharides act as biological response modifiers by binding to specific receptors (such as Dectin-1) on the surface of innate immune cells, including macrophages, neutrophils, and natural killer cells, thereby enhancing their phagocytic activity and cytokine production. The 'Immunsil D3' variant incorporates Vitamin D3 (cholecalciferol) and Zinc (as zinc glycinate) to provide synergistic support for both innate and adaptive immune responses, facilitating T-cell activation and maintaining mucosal barrier integrity. It is used as a prophylactic measure during periods of increased seasonal infections or as an adjunct during recovery from viral and bacterial illnesses.

Brand names
ImmunsilImmunsil D3
Other names
Іммунсіл
02

Targets

CLEC7A (Dectin-1)

Beyond the preview

Go deeper on Immunsil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunsil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call